Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14311260 | 0.89 | HTR2A (0.55) | HTR2AKCNH2CPB1KMT2AMEN1 | |
| SCHEMBL13944389 | 0.87 | SRD5A2 (0.57) | HTR2AKCNH2CPB1KMT2AMEN1 | |
| SCHEMBL28203216 | 0.84 | KMT2A (0.71) | KCNH2KMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL20206416 | 0.82 | POLB (0.60) | HTR2AKMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL3391936 | 0.82 | HSD11B1 (0.69) | HTR2AMGLLHSD11B1 | |
| SCHEMBL28087584 | 0.82 | HTR2A (0.55) | HTR2AKCNH2SLC18A3CPB1KMT2A | |
| SCHEMBL8081266 | 0.82 | MGLL (0.60) | HTR2ASLC18A3KMT2AMEN1MGLL | |
| SCHEMBL3391998 | 0.82 | MGLL (0.69) | KMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL10112201 | 0.82 | HSD11B1 (0.60) | SLC18A3KMT2AMEN1MGLLHSD11B1 | |
| SCHEMBL4040222 | 0.82 | MEN1 (0.47) | HTR2AKCNH2KMT2AMEN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-10654838-B2 | Aminopyridine compounds useful as inhibitors of protein prenylation | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3204380-B1 | NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION | INST NAT SANTE RECH MED (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-20170305892-A1 | NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-10-26 | — | — | US | disclosed |
| US-20170305892-A1 | NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-10-26 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1784401-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-05-16 | — | — | EP | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006024160-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-03-09 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | HTR2A 669/4885KCNH2 120/4885SLC18A3 1616/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | HTR2A 944/4885KCNH2 49/4885SLC18A3 566/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | HTR2A 238/4885KCNH2 2720/4885SLC18A3 44/4885 |
| US-20170305892-A1 | NOVEL AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN PRENYLATION | RCE1, PTAR1, CDK2AP1 | HTR2A 2995/4885KCNH2 3572/4885SLC18A3 3555/4885 |
| US-10654838-B2 | Aminopyridine compounds useful as inhibitors of protein prenylation | RCE1, PTAR1, CDK2AP1 | HTR2A 2891/4885KCNH2 3362/4885SLC18A3 3610/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | HTR2A 238/4885KCNH2 2720/4885SLC18A3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.